Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

TB is considered as one of the oldest documented infectious diseases in the world and is believed to be the leading cause of mortality due to a single infectious agent. Mtb, the causative agent responsible for TB, continues to afflict millions of people worldwide. Furthermore, one-third of the entire world's population has latent TB. Consequently, there has been a worldwide effort to eradicate and limit the spread of Mtb through the use of antibiotics. However, management of TB is becoming more challenging with the emergence of drug-resistant and multi-drug resistant strains of Mtb. Furthermore, when administered, many of the anti-TB drugs commonly present severe complications and side effects. Novel approaches to enhance the host immune responses to completely eradicate Mtb infection are urgently needed. This Special Issue will therefore cover most recent advances in the area of host-directed therapies for TB.

Mycobacterium tuberculosis --- host-directed therapies --- immune responses --- tuberculosis --- lung cancer --- misdiagnosis --- invasive procedure --- revising --- antiplatelet --- aspirin --- immunomodulation --- survival --- Taiwan --- latent infection --- pulmonary --- rabbit --- iron supplementation --- pathology --- immune response --- gene expression --- Perls’ stain --- autophagy --- M. tb --- BCG vaccination --- immune exhaustion --- glutathione --- cytokines --- granulomas --- type 2 diabetes --- co-morbidities --- co-infections --- inflammation --- redox imbalance --- antioxidants

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread globally to pandemic proportions. Although the majority of cases have asymptomatic or mild infections, a significant proportion of cases progress to severe pneumonia and acute respiratory distress syndrome requiring critical care. Opportunistic infections following severe respiratory viral infections have been recognized since the 1918 influenza pandemic. Among critically ill patients with COVID-19, secondary fungal infections caused by Aspergillus and Candida spp. are increasingly described, affecting up to 30% of COVID-19 patients requiring intensive care treatment. This collection of manuscripts focuses on fungal infections complicating COVID-19, including immunological mechanisms and pathogenesis, diagnosis, and treatment.

SARS-CoV-2 --- co-infection --- pulmonary aspergillosis --- ICU --- azole-resistant Aspergillus --- Aspergillus fumigatus --- CAPA --- TR34L98H --- SARS COV-2 --- Aspergillus --- novel coronavirus --- superinfection --- risk factors --- prevalence --- challenges --- immune response --- expert statement --- European Confederation of Medical Mycology --- COVID-19 --- fungaemia --- Saccharomyces --- co-infections --- invasive aspergillosis --- putative --- probable --- Sars-CoV-2 --- PCR --- galactomannan --- classification --- COVID-19 pneumonia --- invasive pulmonary aspergillosis --- diagnosis --- multi-triazole resistance --- COVID-19 associated invasive pulmonary aspergillosis --- coinfection --- diabetes --- bloodstream infection --- Candida glabrata --- echinocandin resistance --- FKS mutation --- candidemia --- candiduria --- oral candidiasis --- mycobiome --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Foamy viruses, currently referred to as spumaretroviruses, are the most ancient retroviruses as evidenced by traces of viral sequences dispersed in all vertebrate classes from fish to mammals. Additionally, infectious foamy viruses circulate in a variety of mammalian species including simian, bovine, equine, caprine, and feline. Foamy viruses have many unique features which led to the division of the retrovirus family into two subfamilies, the Orthoretrovirinae and Spumaretrovirinae. In vitro, foamy viruses have a broad host range and in vivo, human infections have been described due to cross-species transmission from infected nonhuman primates. Thus far, there are no reports of virus-induced disease in humans or in the natural host species. These unique properties of foamy viruses have led researchers to develop foamy viruses as gene therapy vectors to study virus–virus and virus–host interactions for identifying factors involved in virus replication, transmission, and immune regulation that could influence potential clinical outcomes in humans as well as for using endogenous foamy virus sequences in the analysis of host species evolution.

Medicine --- Neurosciences --- spumavirus --- feline illness --- proviral load --- neglected virus --- bovine foamy virus --- infectious clone --- particle release --- cell-free transmission --- foamy virus --- spumaretrovirus --- cross-species virus transmission --- zoonosis --- restriction factors --- immune responses --- FV vectors --- virus replication --- latent infection --- feline foamy virus --- epidemiology --- retrovirus --- Spumaretrovirus --- mountain lion --- Puma concolor --- ELISA --- protease --- reverse transcriptase --- RNase H --- reverse transcription --- antiviral drugs --- resistance --- simian foamy virus --- gibbon --- lesser apes --- co-evolution --- complete viral genome --- equine foamy virus --- isolation --- Japan --- sero-epidemiology --- reptile foamy virus --- endogenous foamy virus --- endogenous retrovirus --- ancient retroviruses --- co-speciation --- foamy virus-host interactions --- viral tropism --- infection --- kidney --- cats --- chronic kidney disease --- chronic renal disease --- integrase --- integration --- co-infections --- NHP --- pathogenesis --- zoonoses --- viral prevalence --- Neotropical primates --- free-living primates --- Brazil --- new world primates --- simian retrovirus --- BFV --- spuma virus --- model system --- animal model --- animal experiment --- miRNA function --- gene expression --- antiviral host restriction --- gene therapy --- in-vivo gene therapy --- hematopoietic stem and progenitor cells --- foamy virus vector --- pre-clinical canine model --- SCID-X1 --- innate sensing --- cGAS --- STING --- foamy viruses --- wild ruminants --- European bison --- red deer --- roe deer --- fallow deer --- seroreactivity --- inter-species transmission --- HSC --- gene marking --- FV gene transfer to HSCs --- gene therapy alternatives --- serotype --- high-throughput sequencing --- replication kinetics --- cytopathic effect --- reverse transcriptase activity --- miRNA expression --- virus-host-interaction --- miRNA target gene identification --- innate immunity --- ANKRD17 --- Bif1 (SH3GLB1) --- replication in vitro --- spumavirus --- feline illness --- proviral load --- neglected virus --- bovine foamy virus --- infectious clone --- particle release --- cell-free transmission --- foamy virus --- spumaretrovirus --- cross-species virus transmission --- zoonosis --- restriction factors --- immune responses --- FV vectors --- virus replication --- latent infection --- feline foamy virus --- epidemiology --- retrovirus --- Spumaretrovirus --- mountain lion --- Puma concolor --- ELISA --- protease --- reverse transcriptase --- RNase H --- reverse transcription --- antiviral drugs --- resistance --- simian foamy virus --- gibbon --- lesser apes --- co-evolution --- complete viral genome --- equine foamy virus --- isolation --- Japan --- sero-epidemiology --- reptile foamy virus --- endogenous foamy virus --- endogenous retrovirus --- ancient retroviruses --- co-speciation --- foamy virus-host interactions --- viral tropism --- infection --- kidney --- cats --- chronic kidney disease --- chronic renal disease --- integrase --- integration --- co-infections --- NHP --- pathogenesis --- zoonoses --- viral prevalence --- Neotropical primates --- free-living primates --- Brazil --- new world primates --- simian retrovirus --- BFV --- spuma virus --- model system --- animal model --- animal experiment --- miRNA function --- gene expression --- antiviral host restriction --- gene therapy --- in-vivo gene therapy --- hematopoietic stem and progenitor cells --- foamy virus vector --- pre-clinical canine model --- SCID-X1 --- innate sensing --- cGAS --- STING --- foamy viruses --- wild ruminants --- European bison --- red deer --- roe deer --- fallow deer --- seroreactivity --- inter-species transmission --- HSC --- gene marking --- FV gene transfer to HSCs --- gene therapy alternatives --- serotype --- high-throughput sequencing --- replication kinetics --- cytopathic effect --- reverse transcriptase activity --- miRNA expression --- virus-host-interaction --- miRNA target gene identification --- innate immunity --- ANKRD17 --- Bif1 (SH3GLB1) --- replication in vitro

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Foamy viruses, currently referred to as spumaretroviruses, are the most ancient retroviruses as evidenced by traces of viral sequences dispersed in all vertebrate classes from fish to mammals. Additionally, infectious foamy viruses circulate in a variety of mammalian species including simian, bovine, equine, caprine, and feline. Foamy viruses have many unique features which led to the division of the retrovirus family into two subfamilies, the Orthoretrovirinae and Spumaretrovirinae. In vitro, foamy viruses have a broad host range and in vivo, human infections have been described due to cross-species transmission from infected nonhuman primates. Thus far, there are no reports of virus-induced disease in humans or in the natural host species. These unique properties of foamy viruses have led researchers to develop foamy viruses as gene therapy vectors to study virus–virus and virus–host interactions for identifying factors involved in virus replication, transmission, and immune regulation that could influence potential clinical outcomes in humans as well as for using endogenous foamy virus sequences in the analysis of host species evolution.

spumavirus --- feline illness --- proviral load --- neglected virus --- bovine foamy virus --- infectious clone --- particle release --- cell-free transmission --- foamy virus --- spumaretrovirus --- cross-species virus transmission --- zoonosis --- restriction factors --- immune responses --- FV vectors --- virus replication --- latent infection --- feline foamy virus --- epidemiology --- retrovirus --- Spumaretrovirus --- mountain lion --- Puma concolor --- ELISA --- protease --- reverse transcriptase --- RNase H --- reverse transcription --- antiviral drugs --- resistance --- simian foamy virus --- gibbon --- lesser apes --- co-evolution --- complete viral genome --- equine foamy virus --- isolation --- Japan --- sero-epidemiology --- reptile foamy virus --- endogenous foamy virus --- endogenous retrovirus --- ancient retroviruses --- co-speciation --- foamy virus-host interactions --- viral tropism --- infection --- kidney --- cats --- chronic kidney disease --- chronic renal disease --- integrase --- integration --- co-infections --- NHP --- pathogenesis --- zoonoses --- viral prevalence --- Neotropical primates --- free-living primates --- Brazil --- new world primates --- simian retrovirus --- BFV --- spuma virus --- model system --- animal model --- animal experiment --- miRNA function --- gene expression --- antiviral host restriction --- gene therapy --- in-vivo gene therapy --- hematopoietic stem and progenitor cells --- foamy virus vector --- pre-clinical canine model --- SCID-X1 --- innate sensing --- cGAS --- STING --- foamy viruses --- wild ruminants --- European bison --- red deer --- roe deer --- fallow deer --- seroreactivity --- inter-species transmission --- HSC --- gene marking --- FV gene transfer to HSCs --- gene therapy alternatives --- serotype --- high-throughput sequencing --- replication kinetics --- cytopathic effect --- reverse transcriptase activity --- miRNA expression --- virus-host-interaction --- miRNA target gene identification --- innate immunity --- ANKRD17 --- Bif1 (SH3GLB1) --- replication in vitro